Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Surg Oncol ; 39(1): 4-16, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22980492

RESUMEN

BACKGROUND: This systematic review has two purposes: to consolidate the current knowledge about clinical effectiveness of electrochemotherapy, a highly effective local therapy for cutaneous and subcutaneous tumors; and to investigate the differences in effectiveness of electrochemotherapy with respect to tumor type, chemotherapeutic drug, and route of drug administration. METHODS: All necessary steps for a systematic review were applied: formulation of research question, systematic search of literature, study selection and data extraction using independent screening process, assessment of risk of bias, and statistical data analysis using two-sided common statistical methods and meta-analysis. Studies were eligible for the review if they provided data about effectiveness of single-session electrochemotherapy of cutaneous or subcutaneous tumors in various treatment conditions. RESULTS: In total, 44 studies involving 1894 tumors were included in the review. Data analysis confirmed that electrochemotherapy had significantly (p < .001) higher effectiveness (by more than 50%) than bleomycin or cisplatin alone. The effectiveness was significantly higher for intratumoral than for intravenous administration of bleomycin (p < .001 for CR%, p = .028 for OR%). Bleomycin and cisplatin administered intratumorally resulted in equal effectiveness of electrochemotherapy. Electrochemotherapy was more effective in sarcoma than in melanoma or carcinoma tumors. CONCLUSIONS: The results of this review shed new light on effectiveness of electrochemotherapy and can be used for prediction of tumor response to electrochemotherapy with respect to various treatment conditions and should be taken into account for further refinement of electrochemotherapy protocols.


Asunto(s)
Antineoplásicos/administración & dosificación , Bleomicina/administración & dosificación , Cisplatino/administración & dosificación , Electroquimioterapia , Neoplasias Cutáneas/tratamiento farmacológico , Antibióticos Antineoplásicos/administración & dosificación , Carcinoma/tratamiento farmacológico , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Humanos , Infusiones Intralesiones , Infusiones Intravenosas , Melanoma/tratamiento farmacológico , Variaciones Dependientes del Observador , Sarcoma/tratamiento farmacológico , Resultado del Tratamiento
2.
Med Biol Eng Comput ; 50(12): 1213-25, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23179413

RESUMEN

Electrochemotherapy, a combination of high voltage electric pulses and of an anticancer drug, has been demonstrated to be highly effective in treatment of cutaneous and subcutaneous tumors. Unique properties of electrochemotherapy (e.g., high specificity for targeting cancer cells, high degree of localization of treatment effect, capacity for preserving the innate immune response and the structure of the extracellular matrix) are facilitating its wide spread in the clinics. Due to high effectiveness of electrochemotherapy in treatment of cutaneous and subcutaneous tumors regardless of histological origin, there are now attempts to extend its use to treatment of internal tumors. To advance the applicability of electrochemotherapy to treatment of internal solid tumors, new technological developments are needed that will enable treatment of these tumors in daily clinical practice. New electrodes through which electric pulses are delivered to target tissue need to be designed with the aim to access target tissue anywhere in the body. To increase the probability of complete tumor eradication, the electrodes have to be accurately positioned, first to provide an adequate extent of electroporation of all tumor cells and second not to damage critical healthy tissue or organs in its vicinity. This can be achieved by image guided insertion of electrodes that will enable accurate positioning of the electrodes in combination with patient-specific numerical treatment planning or using a predefined geometry of electrodes. In order to be able to use electrochemotherapy safely for treatment of internal tumors located in relative proximity of the heart (e.g., in case of liver metastases), the treatment must be performed without interfering with the heart's electrical activity. We describe recent technological advances, which allow treatment of liver and bone metastases, soft tissue sarcomas, brain tumors, and colorectal and esophageal tumors. The first clinical experiences in these novel application areas of electrochemotherapy are also described.


Asunto(s)
Electroquimioterapia/instrumentación , Electroquimioterapia/métodos , Neoplasias/tratamiento farmacológico , Animales , Electrodos , Endoscopios , Humanos
3.
Technol Cancer Res Treat ; 10(5): 475-85, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21895032

RESUMEN

Electrochemotherapy is now in development for treatment of deep-seated tumors, like in bones and internal organs, such as liver. The technology is available with a newly developed electric pulse generator and long needle electrodes; however the procedures for the treatment are not standardized yet. In order to describe the treatment procedure, including treatment planning, within the ongoing clinical study, a case of successful treatment of a solitary metastasis in the liver of colorectal cancer is presented. The procedure was performed intraoperatively by inserting long needle electrodes, two in the center of the tumor and four around the tumor into the normal tissue. The insertion of electrodes proved to be feasible and was done according to the treatment plan, prepared by numerical modeling. After intravenous bolus injection of bleomycin the tumor was exposed to electric pulses. The delivery of the electric pulses did not interfere with functioning of the heart, since the pulses were synchronized with electrocardiogram in order to be delivered outside the vulnerable period of the ventricles. Also the post treatment period was uneventful without side effects. Re-operation of the treated metastasis demonstrated feasibility of the reoperation, without secondary effects of electrochemotherapy on normal tissue. Good antitumor effectiveness with complete tumor destruction was confirmed with histological analysis. The patient is disease-free 16 months after the procedure. In conclusion, treatment procedure for electrochemotherapy proved to be a feasible technological approach for treatment of liver metastasis. Due to the absence of the side effects and the first complete destruction of the treated tumor, treatment procedure for electrochemotherapy seems to be a safe method for treatment of liver metastases with good treatment effectiveness even in difficult-to-reach locations.


Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Bleomicina/administración & dosificación , Carcinoma/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias del Colon Sigmoide/patología , Antibióticos Antineoplásicos/uso terapéutico , Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bevacizumab , Bleomicina/uso terapéutico , Capecitabina , Carcinoma/secundario , Carcinoma/cirugía , Terapia Combinada , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Electroquimioterapia , Estudios de Factibilidad , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/análogos & derivados , Humanos , Hígado/patología , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Persona de Mediana Edad , Necrosis , Oxaloacetatos , Neoplasias del Colon Sigmoide/terapia , Resultado del Tratamiento
4.
Br J Cancer ; 98(2): 388-98, 2008 Jan 29.
Artículo en Inglés | MEDLINE | ID: mdl-18182988

RESUMEN

Electrochemotherapy has a direct cytotoxic effect on tumour cells, and presumably, a vascular disrupting effect. In this study, on the basis of the prediction of the mathematical model, histological evaluation and physiological measurements of the tumours were carried out to confirm that electroporation and electrochemotherapy of tumours have a vascular disrupting action. In the study, SA-1 solid subcutaneous sarcoma tumours in A/J mice were treated by bleomycin (BLM) given intravenously (1 mg kg(-1)), application of electric pulses (8 pulses, 1040 V, 100 micros, 1 Hz) or a combination of both - electrochemotherapy. The vascular effect was determined by laser Doppler flowmetry, power Doppler ultrasonographic imaging and Patent blue staining. The extent of tumour hypoxia was determined immunohistochemically by hypoxia marker pimonidazole and partial pressure of oxygen (pO(2)) in tumours by electron paramagnetic resonance oximetry. Electrochemotherapy with BLM induced good antitumour effect with 22 days, tumour growth delay and 38% tumour cures. The application of electric pulses to the tumours induced instant but transient tumour blood flow reduction (for 70%) that was recovered in 24 h. During this tumour blood flow reduction, we determined an increase in hypoxic tumour area for up to 30%, which was also reflected in reduced tumour oxygenation (for 70%). According to the described mathematical model, endothelial cells lining in tumour blood vessels are exposed to a approximately 40% higher electric field than the surrounding tumour cells, and therefore easily electroporated, allowing access of high BLM concentration to the cytosol. Consequently, electrochemotherapy has, besides the immediate vascular disrupting action, also a delayed one (after 24 h), as a consequence of endothelial cell swelling and apoptosis demonstrated by extensive tumour necrosis, tumour hypoxia, prolonged reduction of tumour blood flow and significant tumour growth delay, and tumour cures. Our results demonstrate that in addition to the well-established direct cytotoxic effect on tumour cells, electrochemotherapy also has an indirect vascular disrupting action resulting altogether in extensive tumour cell necrosis leading to complete regression of tumours.


Asunto(s)
Bleomicina/uso terapéutico , Electroquimioterapia , Electroporación , Endotelio Vascular/efectos de los fármacos , Neovascularización Patológica/tratamiento farmacológico , Sarcoma Experimental/tratamiento farmacológico , Animales , Antibióticos Antineoplásicos/uso terapéutico , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Hipoxia de la Célula/efectos de los fármacos , Estimulación Eléctrica , Femenino , Masculino , Ratones , Modelos Biológicos , Modelos Teóricos , Consumo de Oxígeno/efectos de los fármacos , Flujo Sanguíneo Regional/efectos de los fármacos , Sarcoma Experimental/irrigación sanguínea , Sarcoma Experimental/patología , Células Tumorales Cultivadas
5.
J Med Eng Technol ; 29(6): 288-96, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16287678

RESUMEN

The combined treatment of tumours in which delivery of a chemotherapeutic agent is followed by high voltage electroporation pulses has been termed electrochemotherapy. The electrochemotherapy of tumours located relatively close to the heart muscle can lead to fibrillation of the heart, especially if electroporation pulses are delivered in the vulnerable period of the heart or in coincidence with heart arrhythmias. We built an electroporation pulse delivery algorithm that enables safer use of electrochemotherapy. The algorithm is designed to deliver pulses outside the vulnerable period and to prevent pulses from being generated in the presence of heart arrhythmias. We evaluated the algorithm's performance using records of the Long-Term ST Database, thus simulating real-world conditions. The results of the evaluation, a sensitivity of 91.751%, a positive predictivity of 100.000% and a delivery error rate of 8.268% for electroporation pulse delivery (medians), suggest that the algorithm is accurate and appropriate for application in electrochemotherapy of tumours regardless of tumour location.


Asunto(s)
Antineoplásicos/administración & dosificación , Diagnóstico por Computador/métodos , Quimioterapia Asistida por Computador/métodos , Electrocardiografía/métodos , Electroporación/métodos , Síndrome de QT Prolongado/diagnóstico , Neoplasias/tratamiento farmacológico , Algoritmos , Antineoplásicos/efectos adversos , Sistemas de Liberación de Medicamentos/efectos adversos , Sistemas de Liberación de Medicamentos/métodos , Humanos , Neoplasias/complicaciones , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Fibrilación Ventricular/prevención & control
6.
Ann Biomed Eng ; 29(4): 311-20, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11339328

RESUMEN

The main purpose of our study was to determine the parameters of the postocclusive reactive hyperemia test that could help and provide the clinician with information about the tissue oxygenation, the severity of the disease, and the results of the applied therapies. Near infrared spectroscopy (NIRS) proved to be a valid noninvasive trend monitor useful for investigating the physiology of oxygen transport to tissue. Important advantages of NIRS over transcutaneous oximetry (TcpO2) are: (a) a more dynamic nature of the NIRS signals which reflects more closely the actual response of the peripheral vasculature to the occlusive provocation; (b) larger sampling volume; and (c) the ability of assessing tissue oxygenation at deeper tissue levels. We demonstrated that the time parameters of reactive hyperemia, the rate of reactive hyperemia, and the maximal change during reactive hyperemia, all calculated from the oxyhemoglobin (HbO2) signal of the NIRS, clearly distinguish between healthy volunteers and patients with vascular disorder. The time parameters of reactive hyperemia were significantly longer (p<0.01), and the rate of reactive hyperemia (p=0.01) as well as the maximal change during reactive hyperemia (p=0.02) were significantly lower in patient group compared to healthy volunteers. These parameters were also in good correlation with the values of ankle brachial index (ABI) and the resting values of oxygen partial pressure (TcpO2). Values of the chosen parameters obtained from the HbO2 signal were further compared between groups of diabetic and nondiabetic patients with peripheral vascular disease. Although longer time parameters of reactive hyperemia and lower rates of hyperemic response were detected, the difference between both groups was not statistically significant.


Asunto(s)
Hiperemia/fisiopatología , Enfermedades Vasculares Periféricas/fisiopatología , Anciano , Ingeniería Biomédica , Monitoreo de Gas Sanguíneo Transcutáneo , Estudios de Casos y Controles , Constricción , Femenino , Humanos , Masculino , Persona de Mediana Edad , Consumo de Oxígeno , Oxihemoglobinas/metabolismo , Espectroscopía Infrarroja Corta
7.
Ann Biomed Eng ; 28(2): 168-73, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10710188

RESUMEN

The purpose of this study was to investigate postocclusive hyperemic response using near infrared spectroscopy (NIRS) and transcutaneous oximetry (TcpO2). Five minute arterial occlusion on the calf muscle was performed in six healthy volunteers (mean age 29, range 23-34 years, mean TcpO2 at rest 53 mm Hg, range 47-58 mmHg, and ankle brachial index between 1 and 1.2). Oxygen partial pressure at rest, oxygen consumption (VO2) during ischemia, recovery times and resaturation rates after arterial occlusion were determined and new parameters for evaluation of the level of vascular disorders of lower limbs are suggested. The reproducibility of the signals was studied by repeating the same protocol on each subject four to six times. Repeated measurements showed no significant difference among trials, indicating that the measurements were reproducible. The mean values of the coefficient of variability for suggested parameters varied between 6% and 30% (mean value 17%). Interindividual variations of parameters are higher and can be explained by differences in fat/muscle ratio and in the measured tissue volume of the NIRS signal. Simultaneous measurements of NIRS and TcpO2 showed different responses to ischemic conditions, due to the different physiological levels of oxygen assessment. The combined use of both methods yields deeper insight into conditions of blood flow and tissue oxygenation.


Asunto(s)
Monitoreo de Gas Sanguíneo Transcutáneo/métodos , Pie/irrigación sanguínea , Hiperemia/diagnóstico , Isquemia/diagnóstico , Espectroscopía Infrarroja Corta/métodos , Adulto , Análisis de Varianza , Humanos , Isquemia/fisiopatología , Consumo de Oxígeno , Valores de Referencia , Reproducibilidad de los Resultados
8.
Adv Exp Med Biol ; 471: 497-506, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10659183

RESUMEN

Electrotherapy with low-level direct electric current has been proved to be an effective local treatment of solid tumours. In the presented study an attempt was made to evaluate the effect of a single treatment with electrotherapy on blood perfusion of solid subcutaneous fibrosarcoma Sa-1 tumours in A/J mice. The tissue-staining method with Patent blue-violet dye, the rubidium extraction technique, and the noninvasive near-infrared spectroscopy method were used for this purpose. Results of all methods indicate that perfusion and subsequently oxygenation of tumours were reduced due to application of electrotherapy.


Asunto(s)
Terapia por Estimulación Eléctrica , Fibrosarcoma/sangre , Neoplasias Cutáneas/sangre , Animales , Colorantes , Terapia por Estimulación Eléctrica/métodos , Femenino , Fibrosarcoma/metabolismo , Fibrosarcoma/terapia , Masculino , Ratones , Ratones Endogámicos A , Colorantes de Rosanilina , Rubidio , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/terapia , Espectroscopía Infrarroja Corta , Coloración y Etiquetado/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA